Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MYC oncogene, known to drive myeloma progression, was downregulated in both in vitro and in vivo models when treated with [Au(d2pype)<sub>2</sub>]Cl.
|
31514052 |
2020 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma.
|
31221783 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As proof of concept, we identified a low micromolar potency molecule (compound 30666) that inhibited immunoglobulin production by MM cells and blocked expression of an array of IgH translocation-induced oncogenes (CCND1, FGFR3/MMSET, and MYC) in MM and NHL cell lines.
|
30481117 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ex vivo pharmacodynamic analyses demonstrated that the combination of JQ1 and ricolinostat led to significantly lower MM cell proliferation and increased apoptosis and diminished expression of c-MYC and BCL-2.
|
31015208 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vk*MYC mice under glyphosate exposure developed progressive hematological abnormalities and plasma cell neoplasms such as splenomegaly, anemia, and high serum IgG.
|
31277689 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We developed preclinical models of bone marrow transplantation (BMT) for MM using Vk*MYC myeloma-bearing recipient mice and donor mice that were myeloma naive or myeloma experienced to simulate autologous transplantation.
|
30300141 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunocompetent models, in particular the 5T series and Vk<sup>⁎</sup>MYC models, are increasingly being utilized in preclinical studies and are adding to our knowledge of not only the adaptive immune system but also how the innate system might be enhanced in anti-MM activity.
|
31093282 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, 78% of IgL-MYC translocations co-occur with hyperdiploid disease, a marker of standard risk, suggesting that IgL-MYC-translocated myeloma is being misclassified.
|
31015454 |
2019 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, promoter derepression of TAZ expression sensitizes MM cell lines through a reciprocal reduction in MYC expression using additional therapeutics such as bortezomib, trichostatin A, and panobinostat.
|
31743393 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using the syngeneic Vk*MYC BTZ-resistant immunocompetent transplantable MM murine model, we also demonstrate that mice harboring BTZ-insensitive MM tumors respond to the RV/BTZ combination treatment in terms of decreased tumor burden and improved overall survival (<i>P</i> < .00001).
|
30850386 |
2019 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our experimental results further demonstrate that Co-fuse can identify known driver fusion genes (e.g., IGH-MYC, IGH-WHSC1) in MM, when compared to AML samples, indicating the potential of Co-fuse to aid the discovery of yet unknown driver fusion genes through cohort comparisons.
|
29882166 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we describe the mechanism of MYC activation in MM, the role of MYC in cancer progression, and the therapeutic options to targeting MYC.
|
29467490 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mice deficient for IL-18 were remarkably protected from Vk<sup>∗</sup>MYC MM progression in a CD8<sup>+</sup> T cell-dependent manner.
|
29551594 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The severe combined immune deficiency (SCID) mouse xenograft model revealed that compound 7594-0035 partially decreased the primary tumor growth of Roswell Park Memorial Institute (RPMI)-8226 cells <i>in vivo</i> The novel small molecular compound 7594-0035 described in the present study that targets c-Myc protein is likely to be a promising therapeutic agent for relapsed/refractory MM.
|
30068698 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate myc protein overexpression to be associated with advanced multiple myeloma and poor prognosis.
|
29999206 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since MYC is frequently hyperactivated in MM and inhibition of MYC leads to MM cell death.
|
29472861 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, measuring the levels of 2-HG in the BM supernatant and peripheral blood plasma from patients with precursor PC malignancies such as smoldering MM (SMM) demonstrates that relatively elevated levels of 2-HG are associated with higher levels of c-MYC expression in the BM clonal PCs and with a subsequent shorter time to progression (TTP) to MM.
|
29321378 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, in Vk*MYC mice, commensal bacteria appear to unleash a paracrine signaling network between adaptive and innate immunity that accelerates progression to MM, and can be targeted by already available therapies.
|
30510245 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As such, the Ig and MYC loci are key players in the myeloma genome and including these in any genomic studies is key to understanding the relationship with other abnormalities.
|
29797253 |
2018 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that PCM with MYC related abnormalities in general have advanced tumors and adverse outcomes even with low proliferation.
|
30553464 |
2018 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression profiling of MM cells revealed reversion of the oncogenic MYC-driven transcriptional program by CMLD010509, the most promising rocaglate.
|
28490664 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glutaminase inhibition in multiple myeloma induces apoptosis <i>via</i> MYC degradation.
|
29156762 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The MUC1-C oncoprotein is aberrantly expressed by MM cells, activates MYC and is also necessary for MM cell survival.
|
29050200 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these studies provide a rationale for the clinical translation of CX-5461 as a novel therapeutic approach to target MYC in myeloma.
|
28369725 |
2017 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings reveal a novel mechanism of therapeutic targeting of MYC through the LIN28B/let-7 axis in MM that may impact other MYC-dependent cancers as well.
|
27773931 |
2017 |